Demyelination News and Research

RSS

A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies.

16 Oct 2014

People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study.

10 Sep 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity.

13 Aug 2014

Scientists one step closer to creating viable cell replacement therapy for multiple sclerosis patients

Scientists at The New York Stem Cell Foundation Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.

25 Jul 2014

Western University imaging scientists develop better way to track progression of MS

Imaging scientists at Western University's Robarts Research Institute (London, Canada) have developed a better way to track the progression of Multiple Sclerosis (MS) from its earliest stages.

28 May 2014

MitoQ antioxidant reverses MS-like disease in animal

Researchers at Oregon Health & Science University have discovered that an antioxidant designed more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.

27 Dec 2013

MSCs isolated from MS patients have decreased suppressive function

Multiple sclerosis, an inflammatory autoimmune disease affecting more than one million people worldwide, is caused by an immune reaction to myelin proteins, the proteins that help form the myelin insulating substance around nerves. Demyelination and MS are a consequence of this immune reaction. Bone marrow mesenchymal stem cells have been considered as an important source for cell therapy for autoimmune diseases such as MS because of their immunosuppressive properties.

18 Dec 2013

Auditory processing disorder diagnosis: an interview with Dr Doris-Eva Bamiou, UCL Ear Institute

It is a listening or hearing disorder, which is due to the brain’s defective analysis of sounds, so that individuals who are affected with this disorder cannot make sense of what they hear.

26 Nov 2013

Resveratrol worsens MS-like neuropathology and inflammation, study finds

Resveratrol, a naturally occurring polyphenol compound produced by the skin of red grapes and peanuts, and found in red wine, has been touted as a beneficial supplement due to its anti-inflammatory and antioxidant properties.

1 Oct 2013

Wayne State University initiates groundbreaking multiple sclerosis study

A groundbreaking study in multiple sclerosis focusing on "remyelination in the brain" has been initiated by Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine.

19 Sep 2013

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.

18 Sep 2013

Study shows absence of gene leads to early onset of more serious disease in MS animal model

Scientists led by a UCSF neurology researcher are reporting that they have identified the likely genetic mechanism that causes some patients with multiple sclerosis (MS) to quickly progress to a debilitating stage of the disease while other patients progress much more slowly.

25 Jun 2013

Progenitor cells remain highly dynamic in the adult brain

By monitoring the behavior of a class of cells in the brains of living mice, neuroscientists at Johns Hopkins discovered that these cells remain highly dynamic in the adult brain, where they transform into cells that insulate nerve fibers and help form scars that aid in tissue repair.

10 May 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Androgens could constitute an efficient treatment against multiple sclerosis

Testosterone and its derivatives could constitute an efficient treatment against myelin diseases such as multiple sclerosis, reveals a study by researchers from the Laboratoire d'Imagerie et de Neurosciences Cognitives, in collaboration in particular with the "Neuroprotection et Neurorégénération: Molécules Neuroactives de Petite Taille" unit.

30 Jan 2013

Quantitative MRIs evade multiple sclerosis clinicoradiologic paradox

Quantitative magnetic resonance imaging can detect microstructural changes in the spinal cords of patients with multiple sclerosis that correlate with observed differences in clinical disability, according to a cross-sectional study in Neurology.

28 Jan 2013